Spots Global Cancer Trial Database for tyrosine kinase inhibitor (tki)
Every month we try and update this database with for tyrosine kinase inhibitor (tki) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Unifying Advanced Treatment With Advanced Imaging | NCT03404076 | Gastrointestina... | Dual Energy CT | 18 Years - | Heidelberg University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
